# CS-101 in Patients With β-thalassemia

> **NCT06328764** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **CorrectSequence Therapeutics Co., Ltd** · enrollment: 10 (estimated)

## Conditions studied

- Beta-Thalassemia

## Interventions

- **GENETIC:** CS-101

## Key facts

- **NCT ID:** NCT06328764
- **Lead sponsor:** CorrectSequence Therapeutics Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-03-19
- **Primary completion:** 2026-07-31
- **Final completion:** 2026-07-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2026-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06328764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06328764, "CS-101 in Patients With β-thalassemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06328764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*